AtriCure Analyst Price Targets - Benzinga

AtriCure Inc

ATRCNASDAQ

Trade with Public

Trade with Public

$65.53

5.128.48%

마지막 업데이트: Nov 4, 4:00 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

AtriCure Analyst Price Targets - Benzinga

AtriCure Analyst Price Targets

Wall Street analyst price targets and consensus rating for AtriCure (ATRC).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

3S.Buy

6Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$59Upside to Avg. PT-9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 4, 2026	JP Morgan	Lilia-Celine Lozada	PT Raise	Neutral	$36→$62
Nov 4, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$60→$70
Nov 4, 2026	Needham	Mike Matson	PT Raise	Buy	$64→$70
Nov 4, 2026	BTIG	Marie Thibault	PT Raise	Buy	$63→$70
Oct 21, 2026	Citizens	Daniel Stauder	PT Raise	Market Outperform	$52→$68
Oct 12, 2026	BTIG	Ryan Zimmerman	PT Raise	Buy	$55→$63
Oct 2, 2026	Freedom Capital Markets	Keith Hinton	Downgrade	Buy→Hold	$43→$57
Sep 2, 2026	Needham	Mike Matson	PT Raise	Buy	$45→$64
Aug 27, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$50→$60
Aug 24, 2026	BTIG	Marie Thibault	PT Raise	Buy	$45→$55
Jul 28, 2026	UBS	Priya Sachdeva	PT Cut	Buy	$55→$50
May 6, 2026	Canaccord Genuity	William Plovanic	PT Raise	Buy	$53→$55
Feb 18, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$64→$53
Feb 18, 2026	UBS	Danielle Antalffy	PT Cut	Buy	$60→$55
Feb 18, 2026	Citizens	Daniel Stauder	PT Cut	Market Outperform	$60→$52
Feb 18, 2026	Oppenheimer	Suraj Kalia	Downgrade	Outperform→Perform	—
Feb 18, 2026	BTIG	Marie Thibault	Maintained	Buy	$54
Feb 12, 2026	Needham	Mike Matson	Maintained	Buy	$45
Dec 16, 2025	JP Morgan	Lilia-Celine Lozada	PT Raise	Overweight	$42→$48
Oct 30, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$53→$64

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70

Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.

Benzinga Newsdesk

Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.

Avi Kapoor

AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results

AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.

Avi Kapoor

Needham Maintains Buy on AtriCure, Raises Price Target to $70

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.

Benzinga

PRO
BTIG Maintains Buy on AtriCure, Raises Price Target to $70

BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68

Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.

Benzinga Newsdesk